Page last updated: 2024-11-03

proglumide and Hepatocellular Carcinoma

proglumide has been researched along with Hepatocellular Carcinoma in 3 studies

Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.

Research Excerpts

ExcerptRelevanceReference
"When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition."5.91Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023)
"When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition."1.91Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Shivapurkar, N3
Gay, MD3
He, AR1
Chen, W1
Golnazar, S1
Cao, H3
Duka, T1
Kallakury, B2
Vasudevan, S1
Smith, JP3
Safronenka, A2
Liu, FH1
Malchiodi, ZX1
Tucker, RD2
Kroemer, A1
Ciofoaia, V1
Nadella, S1
Huber, M1
Kruger, AJ1
Kroemer, AHK1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH)[NCT04152473]Phase 118 participants (Actual)Interventional2019-12-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for proglumide and Hepatocellular Carcinoma

ArticleYear
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
    International journal of molecular sciences, 2023, Feb-11, Volume: 24, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cholecystokinin; Fibrosis; Immune Checkpoint Inhibitors; Liver N

2023
Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
    Cancer prevention research (Philadelphia, Pa.), 2021, Volume: 14, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokines, CC; Cholecystokinin; Diet, High-Fa

2021
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Digestive diseases and sciences, 2020, Volume: 65, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Choline Deficiency; Disease Models, Animal; Ep

2020